334 related articles for article (PubMed ID: 35092504)
1. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
2. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
3. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
4. An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment.
Liang XJ; Fu RY; Wang HN; Yang J; Yao N; Liu XD; Wang L
J Immunol Res; 2021; 2021():5564568. PubMed ID: 34212052
[TBL] [Abstract][Full Text] [Related]
5. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
6. Implication of immune cell signature of tumor microenvironment in diffuse large B-cell lymphoma.
Yu H; Fu D; Xu PP; Cheng S; Wang L; Zhang YZ; Zhao WL
Hematol Oncol; 2021 Dec; 39(5):616-624. PubMed ID: 34331367
[TBL] [Abstract][Full Text] [Related]
7. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.
He J; Chen Z; Xue Q; Sun P; Wang Y; Zhu C; Shi W
J Transl Med; 2022 Apr; 20(1):186. PubMed ID: 35468826
[TBL] [Abstract][Full Text] [Related]
8. Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma.
Wang J; Wang Y; Wan L; Chen X; Zhang H; Yang S; Zhong L
Front Immunol; 2023; 14():1230017. PubMed ID: 37790933
[TBL] [Abstract][Full Text] [Related]
9. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
Front Immunol; 2021; 12():732006. PubMed ID: 34745101
[TBL] [Abstract][Full Text] [Related]
10. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
11. OX40 shapes an inflamed tumor immune microenvironment and predicts response to immunochemotherapy in diffuse large B-cell lymphoma.
Lu Y; Li Y; Yu J; Meng S; Bi C; Guan Q; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Armitage J; Zhang H; Fu K; Wang X
Clin Immunol; 2023 Jun; 251():109637. PubMed ID: 37150239
[TBL] [Abstract][Full Text] [Related]
12. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.
Alizadeh AA; Gentles AJ; Alencar AJ; Liu CL; Kohrt HE; Houot R; Goldstein MJ; Zhao S; Natkunam Y; Advani RH; Gascoyne RD; Briones J; Tibshirani RJ; Myklebust JH; Plevritis SK; Lossos IS; Levy R
Blood; 2011 Aug; 118(5):1350-8. PubMed ID: 21670469
[TBL] [Abstract][Full Text] [Related]
13. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
14. Construction of a DLBCL Prognostic Signature Based on Tumor Microenvironment.
Wang G; Qiu C; Zhang C; Hou S; Zhang Q
Expert Rev Hematol; 2021 Jul; 14(7):679-686. PubMed ID: 34139942
[TBL] [Abstract][Full Text] [Related]
15. R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphoma.
Zhao F; Qin Y; Yang J; Liu P; He X; Zhou L; Zhou S; Gui L; Zhang H; Wang X; Jiang S; Zhong Q; Zhou Y; Shi Y
Asia Pac J Clin Oncol; 2020 Dec; 16(6):385-391. PubMed ID: 32779387
[TBL] [Abstract][Full Text] [Related]
16. Expression of N
Xie Z; Li M; Hong H; Xu Q; He Z; Peng Z
Bioengineered; 2021 Dec; 12(1):6115-6133. PubMed ID: 34482808
[TBL] [Abstract][Full Text] [Related]
17. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
Zhao C; Huang R; Zeng Z; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Yan P; Huang Z; Shi J
Aging (Albany NY); 2021 May; 13(10):14131-14158. PubMed ID: 34001679
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]